BIS begins real-value blockchain payment testing with central banks and global firms, advancing tokenized cross-border settlements and digital finance innovation. The Bank for International Settlements is moving blockchain payments into a major new phase. The institution will soon start real-value transaction testing for Project Agorá. Major Central Banks Join BIS Blockchain Payment Trials Bloomberg reports […]
The post BIS Pushes Tokenized Cross-Border Payments Into Real-Value Phase appeared first on Live Bitcoin News.
Base's expansion into Malaysia could catalyze regional blockchain innovation, fostering a vibrant ecosystem and enhancing global crypto collaboration.
The post Base opens Builder’s Loft in Malaysia to support local developers appeared first on Crypto Briefing.
The launch of OTL could significantly enhance global scalability and interoperability in digital finance, reducing operational complexities.
The post Fireblocks, Robinhood, MetaMask join crypto giants to launch Open Transaction Layer appeared first on Crypto Briefing.
Software developers face prosecution risk just for publishing code if CLARITY Act fails. Democrats may withhold support without ethics rules banning officials from crypto trading. CLARITY Act competes for June floor time with housing, farm bill, and FISA deadline. United States Senator Cynthia Lummis warned that domestic blockchain innovation could be put at risk in […]
The post Cynthia Lummis Says Crypto Could Suffer Without CLARITY Act appeared first on Live Bitcoin News.
CRISP's introduction could revolutionize digital voting by enhancing privacy and security, potentially reshaping democratic processes globally.
The post Interfold introduces CRISP for secure, privacy-preserving voting on blockchain appeared first on Crypto Briefing.
Samsung's investment in Dunamu signals a strategic shift towards integrating blockchain and digital finance, potentially reshaping Korea's fintech landscape.
The post Samsung trio to acquire $408 million stake in crypto giant Dunamu from Kakao appeared first on Crypto Briefing.
Overview of Elastos, its goals, token utility, ecosystem, and key considerations for developers and users.
The post Elastos: Blockchain Infrastructure For A Decentralized Internet appeared first on BiteMyCoin.
The post MENA’s Leading Blockchain ADI Partners With Ledger for Institutional Grade Security appeared on BitcoinEthereumNews.com.
Key Highlights ADI Chain partnered with Ledger to bring native $ADI support to Ledger wallets. Users can now securely store and manage $ADI through Ledger’s platform. The partnership reflects the MENA region’s growing focus on regulated blockchain infrastructure and institutional crypto adoption. ADI Chain:- The leading Layer-2 blockchain network from the MENA region, ADI, has signed a major partnership with Ledger to provide institutional-grade security support for its native token, $ADI. As part of the partnership signed by blockchain’s ADI Foundation, Ledger will now support $ADI natively on its platform. Interestignly, ADI Chain is linked to a much larger Abu Dhabi corporate and investment ecosystem. is based in Abu Dhabi and was founded by Sirius International Holding, the digital arm of IHC (International Holding Company), one of the UAE’s largest inve
The post CVS restores Zepbound coverage, adds Eli Lilly’s obesity pill Foundayo appeared on BitcoinEthereumNews.com.
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Shelby Knowles | Bloomberg | Getty Images CVS Health on Thursday said it will restore coverage of Eli Lilly‘s blockbuster weight loss injection Zepbound and start covering its new obesity pill on its standard drug plans – a win for the drugmaker and certain patients who will be able to access more treatment options. CVS will add Zepbound coverage on Oct. 1, and start covering Lilly’s newly approved Foundayo pill on June 1. The move will boost Lilly’s efforts to maintain its dominance over Novo Nordisk in the blockbuster weight loss drug market, as it puts the two drugmakers on equal footing in major plans. It comes a year after CVS struck a deal with Novo Nordisk to make its drug Wegovy the preferred obesity treatment on its standard plans, while dro